X
[{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Announces Pre-Clinical Data on GL0034 to Treat Type 2 Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mankind Pharma Gets CDSCO Panel Nod for Phase I Trial of Anti-Diabetic Drug, MKP10241","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mankind Pharma"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
MKP10241, a new class of anti-diabetic molecules, is designed and developed at the Mankind Research Centre. It is a potent and orally administered small molecule, GPR119 agonist. GPR 119 is highly expressed in pancreatic beta cells and intestinal enteroendocrine cells.
Lead Product(s):
MKP10241
Therapeutic Area: Endocrinology
Product Name: MKP10241
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 19, 2021
Details:
Pre-clinical performance of GL0034 was assessed in a highly relevant type 2 diabetes db/db mouse model. The NCE demonstrated significant outcomes on various diabetic parameters and a marked and meaningful reduction in triglyceride levels.
Lead Product(s):
GL0034
Therapeutic Area: Endocrinology
Product Name: GL0034
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 24, 2020